A man who reportedly shot his ex-wife in Longmont in March entered a plea of not guilty by reason of insanity on Friday. Brandon David Allen, 46, is charged with attempted first-degree murder ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our ...

Now’s the time to stop and rethink Longmont development The problem: a lack of visionary thinking about solving Longmont’s housing problems and developers offering cookie-cutter solutions that ...

Tonight, the Longmont City Council will select a replacement for Council member Marcia Martin, concluding the process initiated by her resignation after seven years of honorable service. While ...

Between 3% and 5% of colorectal cancers exhibit the KRAS G12C mutation. Credit: SewCreamStudio/Shutterstock. Amgen’s LUMAKRAS (sotorasib) and Vectibix (panitumumab ...

The Food and Drug Administration has approved Amgen sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA approvals. Calquence, in combination with chemotherapy bendamustine and ...

Jan 16 (Reuters) - The U.S. Food and Drug Administration approved Amgen's (AMGN.O), opens new tab combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.

The FDA on Thursday agreed to expand the label of Amgen’s KRAS inhibitor Lumakras (sotorasib), opening up its use in colorectal cancer. With the latest approval, Lumakras can now be combined with ...